Crohn’s disease and ulcerative colitis are inflammatory bowel diseases (IBD) leading to abdominal pain, severe diarrhea, fatigue and weight loss. Over 3.5 million Americans and Europeans are estimated to have IBD, yet there is currently no cure, making patients dependent on lifelong symptomatic treatment aimed to reduce intestinal inflammation. Thus, novel and effective treatments for IBD are an urgent and unmet medical need. Selective Inhibitors of Nuclear Export (SINE) function via the inhibition of exportin 1 (XPO1)-mediated nuclear export of over 220 cargoes including important inflammatory regulators such as Nf-κBp65, IκBα and PPARγ.